RhumbLine Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History

RhumbLine Advisers’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72	Hold	3,661	–	–	﹤0.01%	4058
2025 Q4	$95	Sell	3,661 -2,082	-36%	-$283	﹤0.01%	4088
2025 Q3	$745	Sell	5,743 -2,790	-33%	-$383	﹤0.01%	4038
2025 Q2	$2.05K	Sell	8,533 -9,780	-53%	-$2.61K	﹤0.01%	3998
2025 Q1	$3.6K	Sell	18,313 -1,435	-7%	-$743	﹤0.01%	3941
2024 Q4	$10.6K	Buy	19,748 +588	+3%	+$428	﹤0.01%	3874
2024 Q3	$18.2K	Buy	19,160 +2,439	+15%	+$2.77K	﹤0.01%	3825
2024 Q2	$16.3K	Buy	16,721 +9,599	+135%	+$10.5K	﹤0.01%	3900
2024 Q1	$11.3K	Buy	7,122 +1,210	+20%	+$1.46K	﹤0.01%	3847
2023 Q4	$4.69K	Buy	5,912 +330	+6%	+$186	﹤0.01%	3991
2023 Q3	$4.35K	Hold	5,582	–	–	﹤0.01%	4007
2023 Q2	$5.16K	Buy	+5,582	New	+$6.66K	﹤0.01%	4072

RhumbLine Advisers's ADAP Position: Q1 2026 in Review

RhumbLine Advisers held its Adaptimmune Therapeutics (ADAP) position steady in Q1 2026 at 3,661 shares worth $72. The position accounts for ﹤0.01% of the portfolio, ranked #4058.

RhumbLine Advisers first reported a position in ADAP in Q2 2023 and has held it in 12 quarters since. The position peaked at $18.2K in Q3 2024. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

RhumbLine Advisers held 3,661 shares of Adaptimmune Therapeutics worth $72 as of Q1 2026.
RhumbLine Advisers left its Adaptimmune Therapeutics share count unchanged in Q1 2026.
Adaptimmune Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #4058 holding.
RhumbLine Advisers first reported a position in Adaptimmune Therapeutics in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's Adaptimmune Therapeutics position peaked at $18.2K in Q3 2024.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.